These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23881284)

  • 1. Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.
    Wan X; Zhao Y; Burge R; Jiang Y
    Osteoporos Int; 2013 Dec; 24(12):3011-9. PubMed ID: 23881284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
    Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
    Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
    J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
    Ma YL; Zeng QQ; Chiang AY; Burr D; Li J; Dobnig H; Fahrleitner-Pammer A; Michalská D; Marin F; Pavo I; Stepan JJ
    Bone; 2014 Feb; 59():139-47. PubMed ID: 24269280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
    Tsai JN; Zhu Y; Foley K; Lee H; Burnett-Bowie SA; Neer RM; Leder BZ
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2718-23. PubMed ID: 25933031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
    Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
    Miller PD; Delmas PD; Lindsay R; Watts NB; Luckey M; Adachi J; Saag K; Greenspan SL; Seeman E; Boonen S; Meeves S; Lang TF; Bilezikian JP;
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.
    Shiraki M; Sugimoto T; Nakamura T
    Osteoporos Int; 2013 Jan; 24(1):219-26. PubMed ID: 23093347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
    Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
    J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.